301. Multimodal MRI signatures predict ketamine antidepressant response in treatment-resistant depression: a machine-learning analysis of independent clinical trials Authors: P-C Wu, T-P Su, C-T Li, Y-M Bai, M-H Chen Published: 2026 ABSTRACT AbstractBackgroundWhile ketamine produces rapid antidepressant effects in treatment-resistant depression (TRD), response heterogeneity necessitates robust biomarkers to optimize clinical decision-making.Aims & ObjectivesTo validate a machine-learning (ML) framework for predicting ketamine antidepressant response from pre-treatment multimodal neuroimaging features across independent datasets.MethodData from two independent randomized controlled trials were analyzed (training: Trial 1, n=28; independent testing: Trial 2, n=21). Feature extraction combined resting-state functional connectivity, graph-theoretical metrics, and structural morphometry. A K-nearest neighbors classifier was trained using consensus nested cross-validation with ReliefF and minimum redundancy maximum relevance (mRMR) feature selection, with Gaussian noise–based data augmentation to enhance robustness.ResultsThe model generalized well to the independent testing set, achieving 81.0% accuracy and 91.7% specificity. Principal component analysis of the selected features highlighted connectivity patterns involving thalamocortical, visual, and salience networks.Discussion & ConclusionsThis study identifies a multimodal MRI-based ML biosignature of ketamine antidepressant response with good specificity and external generalizability. Accurate non-responder identification supports precision stratification in TRD.